TAVR for All? The Surgical Perspective

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,07 MB, PDF-dokument

  • Xiling Zhang
  • Thomas Puehler
  • Derk Frank
  • Janarthanan Sathananthan
  • Stephanie Sellers
  • David Meier
  • Marcus Both
  • Philipp Blanke
  • Hatim Seoudy
  • Mohammed Saad
  • Oliver J. Müller
  • Søndergaard, Lars
  • Georg Lutter

In spite of the noninferiority of transcatheter aortic valve replacement (TAVR) in high- and intermediate-risk patients, there are still obstacles that need to be overcome before the procedure is further expanded and clinically integrated. The lack of evidence on the long-term durability of the bioprostheses used for TAVR remains of particular concern. In addition, surgery may be preferred over TAVR in patients with bicuspid aortic valve (BAV) or with concomitant pathologies such as other valve diseases (mitral regurgitation/tricuspid regurgitation), aortopathy, and coronary artery disease. In this review, we discuss and summarize relevant data from clinical trials, current trends, and remaining obstacles, and provide our perspective on the indications for the expansion of TAVR.

OriginalsprogEngelsk
Artikelnummer223
TidsskriftJournal of Cardiovascular Development and Disease
Vol/bind9
Udgave nummer7
ISSN2308-3425
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
We acknowledge financial support by Land Schleswig-Holstein within the funding programme Open Access Publikationsfond.

Funding Information:
Outside the submitted work the authors have the following commercial entities: T.P. is a consultant for Abbott. G.L. is a consultant for Edwards Lifesciences, Medtronic, and Abbott. D.F. is a consultant for Edwards Lifesciences and Medtronic and has received research funding from Edwards Lifesciences. M.S. is a consultant for Medtronic. J.S. is a Consultant for Edwards Lifesciences, Boston Scientific and Medtronic and received speaker fees from Edwards. S.S. is a consultant for Edwards Lifesciences and Medtronic. D.M. is supported by the Swiss National Science Foundation (grant P2LAP3_199561), L.S. has recieved consultant fees and/or institutional research grants from Abbott, Boston Scientific, Medtronic and SMT. P.B. is a consultant to Edwards Lifesciences, Abbott, Neovasc, and Circle Cardiovascular Imaging. All other authors have no conflict of interest.

Publisher Copyright:
© 2022 by the authors.

ID: 328426120